	Los Gastos De Explotación		Fecha
Abbott	USD 9.21B	17M	2025-12
Agenus	USD -274.14M	80.46M	2025-09
Agios Pharmaceuticals	USD 141.54M	11.8M	2025-12
Anika Therapeutics	USD 146.8M	867K	2025-09
Arrowhead Research	USD 223.22M	10.86M	2025-12
Enanta Pharmaceuticals	USD 126.59M	346.51M	2025-12
Halozyme Therapeutics	USD 211.07M	74.73M	2025-12
Heron Therapeutics	USD 38.47M	4M	2024-09
Insmed	USD 513.55M	109.86M	2025-12
Integra LifeSciences	USD 368.92M	668.65M	2025-12
Intrexon	USD 61.56M	26.1M	2024-06
J&J	USD 18.97B	2.38B	2025-12
Karyopharm Therapeutics	USD 61.82M	3.24M	2024-12
Ligand Pharmaceuticals	USD 8.29M	32.17M	2025-09
MacroGenics	USD 67M	8M	2025-09
Merit Medical Systems	USD 339.74M	1.8M	2025-12
Rigel Pharmaceuticals	USD 117.61M	35.67M	2025-09
Sangamo BioSciences	USD 33.87M	12.89M	2024-06
Sanofi	EUR 10.51B	1.21B	2025-12
Smith & Nephew	USD 2.52B	84M	2025-12
Stryker	USD 5.2B	505M	2025-12
Surmodics	USD -245.35M	363.49M	2024-09
Veracyte	USD 116M	7.24M	2025-12
Xencor	USD 81.86M	13.35M	2025-12
Zimmer Biomet Holdings	USD 1.94B	277.8M	2025-12

Anika Therapeutics Los Gastos De Explotación - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2026.